$26.89
0.07% yesterday
Nasdaq, Nov 25, 10:01 pm CET
ISIN
US45258J1025
Symbol
IMVT

Immunovant Inc Stock price

$26.89
-3.33 11.02% 1M
-2.06 7.12% 6M
-15.24 36.17% YTD
-6.65 19.83% 1Y
+18.69 227.93% 3Y
+16.39 156.10% 5Y
+16.94 170.25% 10Y
Nasdaq, Closing price Mon, Nov 25 2024
+0.02 0.07%
ISIN
US45258J1025
Symbol
IMVT
Sector

Key metrics

Market capitalization $3.95b
Enterprise Value $3.47b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 8.78
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-352.46m
Free Cash Flow (TTM) Free Cash Flow $-272.30m
Cash position $472.94m
EPS (TTM) EPS $-2.22
P/E forward negative
Short interest 20.41%
Show more

Is Immunovant Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

Immunovant Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

15 Analysts have issued a Immunovant Inc forecast:

15x Buy
100%

Analyst Opinions

15 Analysts have issued a Immunovant Inc forecast:

Buy
100%

Financial data from Immunovant Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
- -
-
100%
- Direct Costs 0.29 0.29
79% 79%
-
-0.29 -0.29
79% 79%
-
- Selling and Administrative Expenses 65 65
28% 28%
-
- Research and Development Expense 287 287
40% 40%
-
-352 -352
37% 37%
-
- Depreciation and Amortization 0.29 0.29
79% 79%
-
EBIT (Operating Income) EBIT -352 -352
36% 36%
-
Net Profit -323 -323
27% 27%
-

In millions USD.

Don't miss a Thing! We will send you all news about Immunovant Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Immunovant Inc Stock News

Neutral
GlobeNewsWire
19 days ago
NEW YORK, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today reported development updates and financial results for its fiscal second quarter ended September 30, 2024.
Neutral
GlobeNewsWire
28 days ago
NEW YORK, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced that data from the Phase 2a trial of batoclimab in Graves' disease will be the subject of an oral presentation of a late-breaking abstract accepted for the 2024 American Thyroid Association (ATA) ...
Neutral
GlobeNewsWire
3 months ago
NEW YORK, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today reported positive results from the Phase 2a trial of batoclimab in Graves' Disease. Immunovant also disclosed data from several proprietary market research studies that showed a consistent unmet need among...
More Immunovant Inc News

Company Profile

Immunovant, Inc. is a clinical-stage biopharmaceutical company. It focuses on enabling normal lives for patients with autoimmune diseases. The company was founded in 2018 and is headquartered in New York, NY.

Head office United States
CEO Peter Salzmann
Employees 207
Founded 2018
Website www.immunovant.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today